Jerome de Vente
Infectious Disease · Long Beach, CANPI 1548208242
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,020 of the $11,120 with a category attached, or 81.1%. 20 manufacturers reported payments, led by Gilead at 36.2% of the total. Reporting peaked in 2023 at $2,758 and has fallen 57.9% since, to $1,161 in 2025.
Across 428 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Viiv Healthcare Company$4K
- Theratechnologies Inc.$1K
- Johnson & Johnson$631
- Merck$416
- AbbVie$241
- plus $855 from 14 others
Across 108 payments — averaging $5523.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$572K
- Janssen Research & Development, LLC$20K
- GSK$4K
What the payments were for
- Consulting fees$1,12510%
- Travel & lodging$8207%
- Food & beverage$9,02081%
- Education$1551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 183 | $4,029 |
| Viiv Healthcare Company | 118 | $3,678 |
| Theratechnologies Inc. | 9 | $1,271 |
| Johnson & Johnson(2 entities) | 31 | $631 |
| Merck | 26 | $416 |
| AbbVie | 21 | $241 |
| GSK | 8 | $161 |
| EMD Serono, Inc. | 6 | $119 |
| Napo Pharmaceuticals Inc | 6 | $105 |
| Janssen Products, LP | 1 | $99 |
| Hologic Sales And Service, LLC | 3 | $73 |
| Pfizer | 3 | $65 |
| Novo Nordisk | 4 | $63 |
| Astellas Pharma US Inc | 2 | $46 |
| Dynavax Technologies Corporation | 2 | $37 |
| Braeburn Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,120 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 136 | $531,915 |
| DescovyEmtricitabine/Tenofov Alafenam | 64 | $143,368 |
| TivicayDolutegravir Sodium | 53 | $140,956 |
| DovatoDolutegravir Sodium/Lamivudine | 35 | $104,581 |
| CabenuvaCabotegravir/Rilpivirine | 12 | $66,999 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $60,883 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $46,285 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $37,228 |
| OzempicSemaglutide | 34 | $36,176 |
| Abilify MaintenaAripiprazole | 11 | $29,553 |
| PrezcobixDarunavir/Cobicistat | 11 | $24,832 |
| Darunavir | 20 | $17,711 |
| JardianceEmpagliflozin | 23 | $17,188 |
| EliquisApixaban | 14 | $9,661 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $4,029 | $721,568212 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Cabenuva, Triumeq | $3,678 | $349,763111 claims |
| Janssen Products, LPSymtuza | $99 | $60,88313 claims |
| Novo NordiskOzempic | $63 | $36,17634 claims |
| Johnson & JohnsonPrezcobix | $631 | $24,83211 claims |
| GSKBreo Ellipta, Incruse Ellipta, Arnuity Ellipta | $161 | $17,71457 claims |
| PfizerEliquis | $65 | $9,66114 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $5,22913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 856 infectious disease providers in California.
Other infectious disease in Long Beach
- Stefan SchneiderLong Beach$219K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.